Furthermore, 2-hydroxyglutarate (2-HG) has been proposed as a key metabolic marker for IDH-mutant gliomas [101], although these are now categorized separately from GBM according to the 2021 WHO classification. This evidence concerns the gene IDH1 and glioma.